returned to control levels when synovial fibroblasts were co-incubated with PGF 2a inhibitor AL8810 whereas inhibition of TGFb signaling with SB505124 had no effect. aSMA gene expression and collagen production were unaffected by inhibition of TGFb or PGF 2a signaling. The increased synovial fibroblast migration in response to FCM could not be counteracted by SB505124, but was partially counteracted by AL8810. Synovial fibroblast proliferation in response to FCM was unaffected either by SB505142 or AL8810. Conclusions: These results indicate that infrapatellar fat can contribute for the development of synovial fibrosis by increasing collagen production, PLOD2 gene expression, cell proliferation and cell migration; all characteristics of a fibrotic process. Based on our results, not TGFb but the more recently discovered pro-fibrotic factor PGF 2a seems partly responsible for the observed effects.
Purpose: Chondroitin sulfate (CS), an interesting candidate for the therapeutic treatment of osteoarthritis (OA), has been shown in clinical trials to reduce swelling and effusion in knee OA. We thus aimed to further investigate the effect of CS alone or in combination with glucosamine sulfate (GS), an anti-COX-2 (celecoxib), or acetaminophen on some synovial membrane anti-angiogenic and inflammatory factors.
Methods: Treatment with CS (200 mg/ml; CSbBio-Active Ò , Bioibérica, Spain), GS (5 mM), celecoxib or acetaminophen alone, and CS in combination with the other mentioned products was investigated on human OA synovial fibroblasts in the presence or absence of IL-1b at 10 and 100 ng/ ml. To determine whether CS has an additional effect with celecoxib or acetaminophen, preliminary experiments were performed to find concentrations of these products that induced about a 50% reduction in prostaglandin E 2 production under IL-1b at 100 ng/ml. A concentration of 10 nM was found for celecoxib and 25 mM for acetaminophen. The expression levels (real time PCR) and/or protein production of vascular endothelial growth inhibitor (VEGI), thrombospondin-1 (TSP-1), hyaluronic acid (HA), secreted phospholipase 2 (sPLA2), and cytosolic phospholipase 2 (cPLA2) were determined using specific primers (expression) and ELISAs (protein). Results: On the anti-angiogenic factors VEGI and TSP-1, IL-1b dosedependently decreased their levels. On cells under basal conditions or treated with IL-1b, CS significantly induced the levels of VEGI expression and TSP-1 production. All the other products tested (GS, celecoxib, and acetaminophen) alone had no effect or decreased these anti-angiogenic factors, but in conjunction with CS their levels were significantly increased. HA production was slightly but significantly increased by IL-1b at 10 ng/ml and a heightened induction was found at 100 ng/ml. CS significantly increased HA under basal conditions and in the presence of IL-1b at 10 ng/ ml. GS had no effect and celecoxib and acetaminophen significantly decreased it. Concomitant incubation of CS with GS, celecoxib, or acetaminophen significantly increased HA production. Interestingly, sPLA2, which is considered an anti-inflammatory (resolving) factor, demonstrated a significant decrease under IL-1b. Incubation with CS alone and in conjunction with celecoxib or acetaminophen significantly increased its level. The inflammatory factor cPLA2 showed significantly decreased expression levels by CS, GS, and the combination of CS and GS. IL-1b markedly and significantly increased it at both concentrations and under IL-1b, CS alone had no effect, but in combination with GS, its level was significantly reduced. Conclusions: The anti-inflammatory effect of CS appears to occur through a number of mechanisms including the inhibition of the anti-angiogenic factors TSP-1 and VEGI as well as sPLA2, a factor associated with an antiinflammatory effect, and through increasing HA production and decreasing cPLA2. Importantly, these effects of CS occurred in the presence of other products, even though those products alone had no or a reverse effect. Purpose: Synovitis is a key factor in osteoarthritis (OA) pathophysiology, contributing to both patient symptoms and disease progression. In this study, using an original methodology comparing normal/reactive (N/R) and inflammatory (I) synovial membranes zones, we investigated the gene expression profiles of synovial cells from these areas and identified differentially regulated pathways. Methods: Synovial cells (SC) were isolated from OA synovial specimens obtained from 12 patients undergoing knee replacement. The inflammatory status of the synovial membrane was characterized by the surgeon according to macroscopic criteria including the synovial vascularization, the villi formation and the hypertrophic aspect of the tissue. At the surgery time, the synovial membrane was dissected and biopsies from N/R and I areas cultured separately for a period of 7 days. Total RNA was extracted using the RNeasy Mini Kit. RNA purity and quality were evaluated using the Experion RNA StdSens Analysis kit (Bio-rad Laboratories). Gene expression profiling between N/R and I areas was performed using Illumina's multi-sample format Human HT-12 BeadChip (Illumina Inc.). Differential analysis was performed with the BRB array tools software. Class Comparison test between N/R and I areas was based on paired t-test where N/R and I were paired for each patient. The biological relevance of up-and down-regulated genes was analyses with Ingenuity Pathways Analysis (IngenuityÒ Systems). Western blot was performed to confirm certain intermediate expression.
97
Results: From among 47000 probes, 17500 were filtered out. Probes with a p-value below than 0.005 were chosen and classified as up-or downregulated ones. By this way, 896 differentially expressed genes between N/ R and I zones were identified. Among these, 576 genes were upregulated (I/ NR > 1.5) and 320 downregulated (I/NR < 0.75). With Ingenuity Pathways Analysis, a significant number of the top ranking differentially expressed genes were identified as inflammatory, Wnt and angiogenic pathways. Interleukin (IL)-6 and -8, chemokines (CXCL1, CXCL2, CXCL5, CXCL6, CXCL16) and arachidonate 5-lipoxygenase (ALOX5) were identified as the most upregulated in I zones in the inflammatory pathway. Interestingly, the alarmin S100A9 was found strongly upregulated in this pathway. Wnt5A and LRP (Low density lipoprotein receptor-related protein) 5 were upregulated whereas FZD (Frizzled homolog) 2 and DKK (dickkopf homolog) 3 were downregulated in the Wnt signaling pathway. Finally, stanniocalcin (STC)-1, an intermediate in angiogenesis was identified as the most upregulated gene in I zones compared to N/R zones. This difference of expression was confirmed at the protein level. Conclusions: Using a unique culture system, this study is the first to identify different expression pattern between two areas of synovial membrane from the same OA patient. These differences concern several key pathways involved in OA pathogenesis, i.e. inflammation, Wnt and angiogenesis. This analysis also provided interesting information regarding new potent intermediates as S100A9 and STC-1. They could be potential targets for chondroitin sulfate, one of the most used molecules in the management of OA. New experiments are being perfomed at the moment to elucidate the potential effect of this molecule on these specific differentially expressed genes in the same culture system. Purpose: Previous epidemiologic studies have established that there is a strong relationship between anterior cruciate ligament (ACL) disruption and the risk for subsequent development of osteoarthritis (OA). Though not normally considered a classical inflammatory arthropathy, OA is often associated with low-grade synovitis. In patients with OA, synovial inflammation is one factor associated with risk of progression of structural joint deterioration and symptoms. The aims of the study were to characterize the synovial features in patients undergoing ACL reconstruction after traumatic ACL rupture and to determine the relationship between inflammation and meniscal and cartilage abnormalities. Methods: The study was conducted in the context of the ACL registry at the Hospital for Special Surgery, which maintains extensive records of preclinical, intraoperative and post-operative data for 1200 patients who have undergone ACL reconstruction for traumatic ACL rupture. Synovial biopsies were collected from 40 patients during arthroscopic surgery and processed for histology and RNA extraction. Synovial features of inflammation, reaction, and degeneration were assessed using a combination histological synovial scoring system developed at our institution in which the following six features were graded: perivascular mononuclear cell infiltration, detritus, mucoid change, fibrosis, increased vascularity and hyperplasia of the synovial lining layer leading to a total combined score of 15. The following clinical data were also collected: age, sex, BMI, date of injury, time to surgery and the intraoperative presence or absence of meniscal and/or cartilage abnormalities. Suprapatellar synovial levels of mRNA for 4 chemokines (IL-8, CCL19, CCL21, and CCL5) and 1 chemokine receptor (CCR7), shown previously to be associated with synovial inflammation in patients undergoing meniscectomy by microarray pathway analysis (C Scanzello A&R 2011), were measured by real-time PCR. Results: Of the 40 patients undergoing synovial biopsy and analysis, 19 were female and 21 male, with mean ages of 29.1 and 38.4, respectively. 75% of the patients exhibited histological evidence of synovial inflammation in the suprapatellar area: 44.1% of patients scored 1 or 2, 44.1% scored 3 or 4, 5.8% scored 5 or 6, and 5.8% scored 7 or 8. Arthroscopically, meniscal abnormalities (mostly tears) were observed in 19/40 patients (47%), and cartilage defects were observed in 16/40 patients (40%). No association was observed between the synovitis score and BMI, date of injury, time to surgery, and frequency of cartilage defects or meniscal pathology. The patients were divided in two groups based on age: 19 of patients older than 30 years and 21 patients younger than 30 yr. Meniscal tears were associated with synovial inflammation in patients older than 30 yr. 16 synovial suprapatellar biopsies from patients > 30 yr were chosen for qPCR analysis, 8 each from patients without synovial inflammation (grade 0-2) and with synovial inflammation (grade 3-8). The levels of CCL5 and CCL19 mRNA were significantly upregulated in biopsy specimens exhibiting inflammation with associated fold-changes of 2.7 (P¼0.0426) and 4.7 (P¼0.0289) respectively. Conclusions: In our study, we observed a high percentage of low-grade synovitis (75%), meniscal tear (47%) and/or cartilage defects (40%) in patients undergoing ACL reconstruction for traumatic ACL rupture. In a cohort of patients > 30 years old, the presence of synovitis correlated with evidence of a meniscal tear, suggesting a relationship between these two pathologic processes. Preliminary analysis of mRNA expression patterns in this group of patients confirmed the upregulation of CCL5 and CCL19. This is in agreement with previously published data (C Scanzello A&R 2011). These two chemokines may play an important contributory role in the pathophysiology of OA particularly in those patients having synovial inflammation. Purpose: A fragment of type II procollagen N-propeptide, PIIBNP, contains the classic integrin binding sequence RGDRGD. This sequence is conserved across species, indicating potential biological function. We have previously shown that recombinant PIIBNP induces death of tumor cells that express integrin a v b 3 and a v b 5 . Data from HUVEC cell tube formation assay, mouse aortic ring assay and mouse corneal assay showed that recombinant PIIBNP inhibits angiogenesis both in vitro and in vivo (1). PIIBNP is synthesized by chondrocytes liberated to matrix in cartilage. The goal of this study was to determine the role that PIIBNP plays in cartilage in keeping cartilage avascular and intact. Methods: Detection of PIIBNP from cartilage. Cartilage was isolated from limbs of P1 mice. Cartilage was smashed by crusher and PIIBNP was extracted with SDS loading buffer, resolved by SDS-PEGE, and detected by western blotting. Mouse chondrocyte isolation. Chondrocytes were obtained by enzymatic dissociation of ventral regions of rib cages from newborn mice. Chondrocytes were incubated with or without the presence of MMP inhibitor for 48 hours. The medium from chondrocytes culture were used as the conditioned medium. Cartilage-aorta co-culture: Bovine and mice bones were used as control in the cartilage-aorta co-culture experiments. Mouse cartilage or bone was placed into inserts of a 24-well plate and cocultured with aorta in 3D matrigel for 8 days. The microvessel outgrowth was visualized under a light microscope (NIKON ECLIPS E800) and images were digitally photographed using a Q capture Retiga 2000R camera, and quantified with an Image J software. Results: We have been able to detect PIIBNP in cartilage ( Fig. 1A) and chondrocytes conditioned medium (Fig. 1B) . In order to reasonably hypothesize an effect of PIIBNP in cartilage, we sought to determine weather cartilage inhibits angiogenesis in mouse aortic ring assays. The results from cartilage-aorta coculture experiments showed that microvessel outgrowth was seen only in control and in the presence of bone, but not in the presence of cartilage ( Fig. 2A) . Since we and other have detected PIIBNP in cartilage, it is possible that the PIIBNP in cartilage inhibited the microvessel outgrowth. To further confirm this, we performed aorta angiogenesis assay in the presence of chondrocyte conditioned medium and found that the chondrocyte conditioned medium inhibited 80 percent of the microvessel outgrowth as compared with the control (Fig B) . MMT inhibitor GM6001 inhibits the production of PIIBNP and the cartilage treated with GM6001 did not inhibit microvessel outgrowth in mouse aortic ring assay. These data suggested that natural PIIBNP in cartilage inhibits angiogenesis. To further investigate the mechanism behind the antiangiogenesis of PIIBNP, we treated HUVEC cells in culture with recombinant proteins. Treatments with PIIBNP, but not GST or mPIIBNP, induced disappearance of VE-cadherin at cell-cell junctions (Fig 3A) , suggesting that the engagement of PIIBNP on cell surface elicited a signaling events involved in the inhibition of angiogenesis by PIIBNP. This hypothesis is supported by the fact that the PIIBNP, but not GST or mPIIBNP, induced activation of the Src kinase ( Fig 3B) , consistent with previous report that integrin a v b 3 signaling induces Src activation and VE-cadherin internalization. Conclusions: We previously showed that recombinant PIIBNP induced tumor cell death via binding to integrin a v b 3 and a v b 5 , and suppresses tumor growth in nude mice. The data presented here suggested that the natural occurring PIIBNP in cartilage most likely inhibits angiogenesis. We have detected the existence of PIIBNP from P1 chondrocyte conditioned medium which also inhibits angiogenesis. Since PIIBNP reaches the highest level during cartilage formation and it kills tumor cell, it is an excellent candidate for the molecular mechanism by which cartilage remains avascular and intact. Ă
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